Federated Hermes, Inc. Insmed Inc Transaction History

Federated Hermes, Inc.

$43.6 Billion
Q3 2024

A detailed history of Federated Hermes, Inc. transactions in Insmed Inc stock. As of the latest transaction made, Federated Hermes, Inc. holds 42,983 shares of INSM stock, worth $2.85 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

42,983

Previous 10,063 327.14%

Holding current value

$2.85 Million

Previous $674,000 365.43%

% of portfolio

0.01%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$62.0 - $79.01 $2.04 Million - $2.6 Million	32,920 Added 327.14%	42,983 $3.14 Million
Q2 2024 Aug 08, 2024	BUY	$22.0 - $69.71 $219,538 - $695,636	9,979 Added 11879.76%	10,063 $674,000
Q1 2024 May 14, 2024	SELL	$25.72 - $29.94 $668 - $778	-26 Reduced 23.64%	84 $2,000
Q4 2023 Jan 31, 2024	SELL	$23.42 - $31.74 $384,860 - $521,583	-16,433 Reduced 99.34%	110 $3,000
Q3 2023 Nov 13, 2023	BUY	$19.86 - $26.93 $328,543 - $445,502	16,543 New	16,543 $417,000
Q3 2019 Nov 14, 2019	SELL	$15.49 - $25.78 $3.86 Million - $6.42 Million	-249,177 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$23.0 - $32.19 $2.04 Million - $2.86 Million	-88,793 Reduced 26.27%	249,177 $6.38 Million
Q1 2019 May 10, 2019	BUY	$13.91 - $31.15 $4.7 Million - $10.5 Million	337,970 New	337,970 $9.83 Million
Q2 2018 Aug 10, 2018	SELL	$20.0 - $29.72 $20,320 - $30,195	-1,016 Closed	0 $0
Q1 2018 May 09, 2018	SELL	$21.69 - $32.99 $944,577 - $1.44 Million	-43,549 Reduced 97.72%	1,016 $23,000
Q4 2017 Feb 14, 2018	BUY	$26.43 - $31.78 $761,818 - $916,026	28,824 Added 183.11%	44,565 $0
Q3 2017 Nov 13, 2017	BUY	$11.61 - $31.21 $182,753 - $491,276	15,741	15,741 $491,000

Others Institutions Holding INSM

# of Institutions

465

Shares Held

182M

Call Options Held

2.27M

Put Options Held

3.33M

View Full List

About INSMED Inc

Ticker INSM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 135,476,992
Market Cap $8.98B
Description
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversibl...

More about INSM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Federated Hermes, Inc. with notifications on news.

Account

Federated Hermes, Inc. Insmed Inc Transaction History